CAMBRIDGE, Mass.--(BUSINESS WIRE)--June 22, 2006--FoldRx Pharmaceuticals, Inc. announced today the publication of a study by Susan Lindquist and collaborators that defines the role of a key protein and biological pathway implicated in Parkinson disease. The research, which appears in the online edition of Science, advances the understanding of Parkinson disease and points the way toward new treatment approaches. The study also underscores the potential of the yeast-based model FoldRx is using as a discovery engine for drugs to treat complex neurodegenerative diseases.
